Observational studyInternational journal of obesity (2005)2024
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study.
Observational study in International journal of obesity (2005), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.Diabetes, obesity & metabolism · 2026Observational
- Long-term outcomes after endoscopic sleeve gastroplasty: impact of clinician follow-up and lifestyle engagement.Surgical endoscopy · 2026Article
- Association between pre-operative computed tomography-based adipose tissue quantification and post-transplant dyslipidemia in renal transplantation recipients.Frontiers in nutrition · 2026Article
- Long-Term Weight Loss in Adults With Overweight or Obesity Using a Breath Biofeedback mHealth App: A One-Year Follow-Up of a Randomized Trial.Obesity science & practice · 2025Article
- Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications.Biomedicines · 2025Review
- Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application.Advances in therapy · 2025 · on this mapArticle
- Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study.Advances in therapy · 2025Observational
- Emerging Trends in Endoscopic Bariatric Therapies: Personalization Through Genomics and Synergistic Pharmacotherapy.Journal of clinical medicine · 2025Review
- Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.Diabetes, obesity & metabolism · 2025 · on this mapReview
- Impact of Anti-obesity Medication Initiation and Duration on Weight Loss.Obesity science & practice · 2025Article
- Mechanisms and treatment of obesity-related hypertension-Part 2: Treatments.Clinical kidney journal · 2025Review
- GLP-1 and the Neurobiology of Eating Control: Recent Advances.Endocrinology · 2025Review
- Prognostic Value of the Triglyceride-Glucose Index Combined with Non-HDL-C/HDL-C Ratio for Predicting Coronary Microvascular Dysfunction in ACS Patients Post-PCI.International journal of general medicine · 2025Article
- Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.Obesity pillars · 2024Review
- Incretin-based therapies for the treatment of obesity-related diseases.npj metabolic health and disease · 2024Review
- Impact of Selected Glucagon-like Peptide-1 Receptor Agonists on Serum Lipids, Adipose Tissue, and Muscle Metabolism-A Narrative Review.International journal of molecular sciences · 2024Review
- Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Therapeutic Advances in Obesity: How Real-World Evidence Impacts Affordability Beyond Standard of Care.Pragmatic and observational research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND/
objectiveThere are limited real-world studies assessing semaglutide weight loss and associated comorbidity and metabolic outcomes over periods ≥ 6 months. We aim to assess weight loss, metabolic, and cardiovascular outcomes of 12 months of semaglutide. SUBJECT/
methodsWe conducted a multicentered retrospective cohort study on semaglutide use. We included patients with a body-mass index (BMI) ≥ 27 kg/m INTERVENTION/
methodsWe assessed weight loss outcomes of subcutaneous semaglutide for 12 months. The primary endpoint was total body weight loss percentage (TBWL%) at 12 months. Secondary endpoints included proportion of patients achieving ≥5%, ≥10%, ≥15%, and ≥20% weight loss, and improvements in metabolic, cardiovascular, and comorbidities after 12 months of follow-up.
resultsWe included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI 40.9 [9.6] kg/m
conclusionsSemaglutide demonstrated notable improvement in obesity, metabolic, and cardiovascular disease risk outcomes in a clinical setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.